We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
03 Mar 20
In October 2018, then-home secretary Sajid Javid passed a law making the use of medicinal cannabis to treat…
03 Mar 20
The portfolio of non-core assets includes over-the-counter (OTC) and prescription pharmaceutical products and is part of Takeda’s growth…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Feb 20
The deal expands Lilly’s portfolio of medicines with the addition of lebrikizumabfor, for atopic dermatitis and QBREXZA for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
The new type 2 diabetes treatment is a daily pill containing empagliflozin, linagliptin and extended release metformin hydrochloride
17 Jan 20
The new manufacturing facility is designed to have advanced features based on the efficiency of the existing facilities…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Jan 20
Lilly will expanding its portfolio of Phase 3 medicines with the addition of lebrikizumabfor for atopic dermatitis and…
Asset ManagementActive Pharmaceutical Ingredients and IntermediatesPharmaceuticals
23 Sep 19
Rybelsus is currently being reviewed by various regulatory agencies across the world, including the European Medicines Agency and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Sep 19
Phase III trial TAGS is designed to evaluate LONSURF in combination with best supportive care (BSC), with placebo…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
27 Aug 19
The closing of the transaction is subject to the signing of a consent decree by Bristol-Myers Squibb and…
21 Aug 19
The FDA acceptance is based on the previously announced positive results of two global Phase 3 studies in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates